Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Atnahs Pharma UK Ltd., Sovereign House, Miles Gray Road, Basildon, Essex, SS14 3FR, UK
Synacthen Ampoules 250 mcg.
| Pharmaceutical Form |
|---|
|
Solution for injection or infusion. A clear colourless aqueous solution for intramuscular injection or intravenous infusion in a 1 mL clear glass ampoule. |
Tetracosactide acetate 250 micrograms per ampoule.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Tetracosactide |
Tetracosactide acetate consists of the first 24 amino acids occurring in the natural corticotropic hormone (ACTH) sequence and displays the same physiological properties as ACTH. In the adrenal cortex, it stimulates the biosynthesis of glucocorticoids, mineralocorticoids, and, to a lesser extent, androgens, which explains its therapeutic effect in conditions responsive to glucocorticoid treatment. |
| List of Excipients |
|---|
|
Acetic acid |
The ampoules are colourless glass Ph.Eur type I.
Synacthen Ampoules comes in cardboard boxes of 1 ampoule and 5 ampoules of 1 ml.
Not all pack sizes may be marketed.
Atnahs Pharma UK Ltd., Sovereign House, Miles Gray Road, Basildon, Essex, SS14 3FR, UK
PL 43252/0026
25 June 1998
| Drug | Countries | |
|---|---|---|
| SYNACTHEN | Australia, Estonia, Ireland, Lithuania, Malta, Netherlands, New Zealand, Turkey, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
